These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 30762304)

  • 61. Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.
    Maharaj AR; Wu H; Hornik CP; Balevic SJ; Hornik CD; Smith PB; Gonzalez D; Zimmerman KO; Benjamin DK; Cohen-Wolkowiez M;
    JAMA Pediatr; 2020 Oct; 174(10):e202422. PubMed ID: 32501511
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.
    Ghobadi C; Johnson TN; Aarabi M; Almond LM; Allabi AC; Rowland-Yeo K; Jamei M; Rostami-Hodjegan A
    Clin Pharmacokinet; 2011 Dec; 50(12):809-22. PubMed ID: 22087867
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Physiologically Based Pharmacokinetic Modeling of Renally Cleared Drugs in Pregnant Women.
    Dallmann A; Ince I; Solodenko J; Meyer M; Willmann S; Eissing T; Hempel G
    Clin Pharmacokinet; 2017 Dec; 56(12):1525-1541. PubMed ID: 28391404
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Investigating the Role of Altered Systemic Albumin Concentration on the Disposition of Theophylline in Adult and Pediatric Patients with Asthma by Using the Physiologically Based Pharmacokinetic Approach.
    Rasool MF; Khalid R; Imran I; Majeed A; Saeed H; Alasmari F; Alanazi MM; Alqahtani F
    Drug Metab Dispos; 2020 Jul; 48(7):570-579. PubMed ID: 32393652
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children.
    Johnson TN; Rostami-Hodjegan A; Tucker GT
    Clin Pharmacokinet; 2006; 45(9):931-56. PubMed ID: 16928154
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children.
    Vinks AA; Emoto C; Fukuda T
    Clin Pharmacol Ther; 2015 Sep; 98(3):298-308. PubMed ID: 26073179
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice.
    Johnson TN; Rostami-Hodjegan A
    Paediatr Anaesth; 2011 Mar; 21(3):291-301. PubMed ID: 20497354
    [TBL] [Abstract][Full Text] [Related]  

  • 68. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
    Edginton AN; Schmitt W; Willmann S
    Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Theoretical versus empirical allometry: Facts behind theories and application to pharmacokinetics.
    Mahmood I
    J Pharm Sci; 2010 Jul; 99(7):2927-33. PubMed ID: 20127826
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Population pharmacokinetics of rabeprazole and dosing recommendations for the treatment of gastroesophageal reflux disease in children aged 1-11 years.
    McLeay SC; Green B; Treem W; Thyssen A; Mannaert E; Kimko H
    Clin Pharmacokinet; 2014 Oct; 53(10):943-57. PubMed ID: 25168707
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Dosage Adjustment for Ceftazidime in Pediatric Patients With Renal Impairment Using Physiologically Based Pharmacokinetic Modeling.
    Zhou J; You X; Ke M; Ye L; Wu W; Huang P; Lin C
    J Pharm Sci; 2021 Apr; 110(4):1853-1862. PubMed ID: 33556385
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Allometry Is a Reasonable Choice in Pediatric Drug Development.
    Liu T; Ghafoori P; Gobburu JV
    J Clin Pharmacol; 2017 Apr; 57(4):469-475. PubMed ID: 27649629
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Population pharmacokinetic analysis during the first 2 years of life: an overview.
    Marsot A; Boulamery A; Bruguerolle B; Simon N
    Clin Pharmacokinet; 2012 Dec; 51(12):787-98. PubMed ID: 23179579
    [TBL] [Abstract][Full Text] [Related]  

  • 75. State-of-the-Art Review on Physiologically Based Pharmacokinetic Modeling in Pediatric Drug Development.
    Yellepeddi V; Rower J; Liu X; Kumar S; Rashid J; Sherwin CMT
    Clin Pharmacokinet; 2019 Jan; 58(1):1-13. PubMed ID: 29777528
    [TBL] [Abstract][Full Text] [Related]  

  • 76. A unified pharmacokinetic approach to individualized drug dosing.
    Begg EJ; Chin PK
    Br J Clin Pharmacol; 2012 Mar; 73(3):335-9. PubMed ID: 21851378
    [No Abstract]   [Full Text] [Related]  

  • 77. Preterm Physiologically Based Pharmacokinetic Model. Part II: Applications of the Model to Predict Drug Pharmacokinetics in the Preterm Population.
    Abduljalil K; Pan X; Pansari A; Jamei M; Johnson TN
    Clin Pharmacokinet; 2020 Apr; 59(4):501-518. PubMed ID: 31587145
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.
    Ince I; Knibbe CA; Danhof M; de Wildt SN
    Clin Pharmacokinet; 2013 May; 52(5):333-45. PubMed ID: 23463352
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Ontogeny of Hepatic Drug Transporters and Relevance to Drugs Used in Pediatrics.
    Elmorsi Y; Barber J; Rostami-Hodjegan A
    Drug Metab Dispos; 2016 Jul; 44(7):992-8. PubMed ID: 26712821
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Drug development perspective on pharmacokinetic studies of new drugs in patients with renal impairment.
    Lalonde RL; Wagner JA
    Clin Pharmacol Ther; 2009 Nov; 86(5):557-61. PubMed ID: 19776736
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.